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Abstract: Monitoring of anti-drug antibodies (ADAbs) or serum concentrations of biologicals 
in treatment of rheumatoid arthritis could provide an explanation for a loss of efficacy and help 
in the choice of subsequent medication. Current clinical practices do not generally include such 
monitoring of tumor necrosis factor (TNF)-α blockers on a routine basis. The main aims of 
this study were to estimate the probabilities of optimal and nonoptimal treatment decisions if 
infliximab or adalimumab drug trough level (DL) and ADAbs are tested or not in rheumatoid 
arthritis, and to model cost-effectiveness of performing such monitoring on a routine basis. 
Data on DLs and ADAbs concentrations were obtained in Finland from clinically requested 
monitoring analyses of 486 and 1,137 samples from patients on adalimumab and infliximab, 
respectively. DL was within the target range in 42% of samples from adalimumab- and 50.4% of 
infliximab-treated patients. ADAbs were detected in approximately 20% and 13.5% of samples 
from adalimumab- and infliximab-treated patients, respectively. ADAbs were found in 52.3% 
and 41.3% of those with low adalimumab or infliximab DLs, respectively. The monitoring data 
were incorporated into probabilities for making the optimal treatment decision. Economic impact 
of clinical decision-making was modeled in a short-term (3–6 months) scenario with 100 hypo-
thetical patients. In the model, the combined measurement of DLs and ADAbs was cost-saving 
compared to the nontesting scenario when the monitoring results affected the treatment decision 
in at least 2–5 of 100 patients, a proportion which is easily exceeded in real-life clinical practice. 
This study indicates that routine monitoring of drug level and ADAbs is cost-beneficial in clinical 
practice, thereby improving the decision-making process in using TNF-α blockers.
Keywords: anti-TNF drugs, anti-drug antibodies, trough level measurement
Background
Biological pharmaceuticals, especially the tumor necrosis factor (TNF)-α blockers, are 
widely used for the treatment of chronic inflammatory diseases such as rheumatoid arthritis 
(RA), psoriasis, and Crohn’s disease. However, more than one-third of these patients either 
do not respond to the treatment or lose their initial response within a few years.1,2 The failure 
of TNF-α blockers has increasingly been attributed to generation of anti-drug antibodies 
(ADAbs), as several studies have demonstrated association between the emergence of 
ADAbs, low serum drug concentration, and impaired clinical efficacy.3–7
Current clinical practices in Finland do not generally include routine monitoring 
of ADAbs or serum concentrations of any biological, although this information could 
provide an explanation for partial or complete loss of efficacy and help in the choice of 
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subsequent medication. In some other countries, monitoring is 
likely to become part of routine care of patients with inflam-
matory bowel diseases, especially in the context of loss of 
response. On the basis of the drug levels and ADAbs, Vincent 
et al1 have proposed a model algorithm for helping take a 
rational decision between switching the ongoing biological 
drug to one with the same or another mode-of-action and 
changing the dose of the ongoing drug.
The rationale of monitoring drug level and ADAbs in 
TNF-α-treated patients is based on multiple reasons such 
as lost efficacy, primary non-responsiveness, and workup 
of adverse events. When a patient has become clearly 
immunized against a biological, as indicated by a high level 
of ADAbs in serum, that drug is destined to fail.3 If the 
immunization is not noticed, the treatment is often continued 
and the drug dose is further increased, apparently resulting 
in needless costs. However, with some patients who have 
ADAbs, addition of methotrexate or increase in the drug 
dose may result in improved drug trough level (DL). In some 
patients with abrupt loss of efficacy of one biological due 
to ADAbs, the whole mode-of-action may be inadequately 
abandoned. On the other hand, if a drug concentration lower 
than the target range drug concentration leads to the loss 
of efficacy in the absence of ADAbs, a dose increase could 
result in improved clinical efficacy, although drug costs are 
simultaneously increased, and increasing the dose of TNF-α 
blocker may not necessarily provide additional efficacy.8 To 
conclude, systematic monitoring of drug concentrations and 
ADAbs could be potentially beneficial and economically jus-
tified, especially given the high costs of biopharmaceuticals 
and the complexity of clinical decision-making.
Several real-life data studies have shown that costs of 
different TNF-α blockers are not equal, for instance, because 
dose escalations are more frequent with some of them com-
pared to others. This is obviously because of the varying 
tendency to generate ADAbs.9–14 The economic impact of 
drug level and ADAb monitoring is, however, not studied in 
the real-life setting. The aim of this study was to estimate the 
probability of optimal and nonoptimal treatment decisions if 
the drug levels and ADAbs of the two most used monoclonal 
antibody drugs in RA – infliximab and adalimumab – are 
tested or not, and based on this information, to explore the 
economic implications of the routine testing.
Methods
laboratory data
Real-life data on DLs and ADAb concentrations of infliximab 
and adalimumab formed the database used in this study. 
The data were obtained from the clinical sample registry of 
United Medix Laboratories Ltd in Helsinki, Finland. All the 
samples included in the database had been sent to the labora-
tory on a clinical basis, ie, none of the samples were from 
clinical studies. The DLs had been analyzed using enzyme-
linked immunosorbent assay, and the ADAb was analyzed 
by radioimmunoassay.3,15,16 All the ADAb measurements 
and the adalimumab DLs had been outsourced to Sanquin 
Diagnostic Services, Amsterdam, the Netherlands, while 
approximately half of the infliximab DLs were analyzed by 
the United Medix Laboratories using ProMonitor test kit 
(Progenica, Derio, Spain).
The use of samples in the study has been approved by the 
coordinating ethical review board of the hospital district of 
Helsinki and Uusimaa (ref no 406/13/03/00/15).
Population stratification according to DL 
and aDab
The “optimal level” or target level of infliximab was defined 
as $2 µg/mL and that of adalimumab as $5 µg/mL, while the 
“low level” was defined as ,2 and ,5 µg/mL, respectively. 
The positivity in the ADAb test was defined as $12 U/mL 
for both infliximab and adalimumab ADAbs. The patient 
population stratification in the analysis was based on cross 
tabulation of the real-life DL and ADAb results.
For adalimumab, the lower limit of the target range 
(5 µg/mL) was taken from the study with RA patients and 
follows the average used in a previous study.17 For infliximab, 
we chose 2 µg/mL as the lower limit in order to not exagger-
ate the number of patients with low drug level.
likelihood of changes in drug use
The data on DLs and ADAbs were incorporated into transition 
probabilities and states in a Markov model for determining 
the optimal treatment in the following 6-month cycle. States 
in the Markov model were 1) the first TNF-α blocker, 2) the 
second biological (TNF-α blocker or non-TNF drug), and 
3) quitting biologicals. Any switch to a third biological was 
not taken into account. Transition probabilities related to the 
nonoptimal treatment response (nonresponse) in the absence 
of knowledge of DL and ADAb values were derived from 
previous literature for both the first-line treatment (European 
League Against Rheumatism [EULAR] response at 6 and 
12 months) and the second-line treatment.18,19 In the case of 
EULAR nonresponse, the stratified data on DLs and ADAbs 
were then used to determine the optimal individualized 
treatment decision distribution according to a simplified 
treatment decision algorithm.1 The Markov model was used 
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to illustrate drug survival and expected medication in the 
population as a result of optimal switches between the drugs 
within a 3-year scenario.
cost estimation
In the second stage, economic impact of clinical decision-
making was modeled in a short-term (3–6 months) scenario 
with 100 hypothetical patients. A wrong clinical decision 
was defined to lead to ineffective treatment for at least 
3–6 months, according to the typical follow-up visit frequen-
cies of RA patients treated with biologicals in Finland. The 
patient’s condition was assumed to be still suboptimal at the 
next visit, thereby leading to the need for further treatment 
modifications.
The cost of 1-month nonoptimal treatment was estimated 
to be approximately €1,471 in total, including drug cost 
(€1,140, the drug cost estimate per month of subcutaneous 
TNF-α blocker without value added tax), travel and lost 
working and leisure time costs for a laboratory visit (€17.4), 
costs of the possible standard safety-related laboratory tests 
(€6.8), travel and lost working and leisure time cost for a 
follow-up visit to an outpatient specialist clinic (€66.6), 
and specialist visit (€240.6). Long-term efficacy-related 
costs were not modeled. Cost of resources was valued 
according to the national unit costs converted to the value 
of year 2013.20
Results
Distribution of infliximab and adalimumab 
Dls and aDab results in Finland
DLs in 42.0% of samples were within the “optimal range” 
(5–10 µg/mL or higher), while 35.8% had a “low level” 
(“DL optimal” and “DL low” in Figure 1A). Approximately 
20% of adalimumab users had any ADAbs ($12 AU/mL) 
(sum of “ADAb+” in Figure 1A). In the dataset, approxi-
mately 15% reached levels more than 30 AU/mL. Of the 
samples with optimal DL, 97.1% (198/204) contained no 
adalimumab ADAbs. On the contrary, of the 174 samples 
with low adalimumab level, 52.3% were positive for ADAbs 
(not reported in Figure 1).
In the database, a total of 1,137 simultaneous infliximab 
DL and ADAb results were found; 50.4% of the DLs were 
within the “optimal range” (2–10 µg/mL or higher), while 
32.4% were below this “low level” (“DL optimal” and “DL 
low” in Figure 1B). Approximately 13.5% of patients had anti-
infliximab antibodies (sum of “ADAb+” in Figure 1B).
In parallel with adalimumab, 99.8% of the samples with 
optimal DL were negative for infliximab ADAbs, while 
ADAbs were found in 41.3% of those with low DL (not 
reported in Figure 1).
The dataset also indicated that the distributions of DLs 
and ADAbs were skewed, and the association between these 
was nonlinear. The distributions were actually somewhat 
exponential. The joint distributions of DLs and ADAbs were 
also different for adalimumab and infliximab, and so the 
relationship between DL and ADAb is not fully consistent 
for adalimumab and infliximab.
Decision-making model and expected 
drug modifications
The algorithm by Vincent et al1 was used to build up a 
Markov model. However, the option for optimal DL with 
detectable ADAbs was removed because only a few patients 
were classified in this group in our laboratory dataset for 
adalimumab and for infliximab. Moreover, to avoid overes-
timation of the economic impact of testing, dose increase 
was not allowed. This also reflects the real-life situation 
in Finland. National reimbursement statistics in Finland 
indicate that dose increase is not very widely used (unpub-
lished data from Social Insurance Institutions). Instead, 
the patients who would have needed dose escalation (low 
trough level and no ADAb) were treated as those switch-
ing to another TNF-α blocker or a non-TNF biological. 
When this simplified algorithm was used in conjunction 
with our laboratory dataset, the Markov model predicted 
that within the following 3 years, 40% of those on adali-
mumab (Figure 2A) and 50% of the patients on infliximab 
(Figure 2B) would need drug treatment modifications. We 
assumed that a small fraction of patients totally quit using 
biologicals.
cost analyses
Patient distributions according to DL and ADAb database 
(Figure 1) and Markov model (Figure 2) indicate that lack 
of information about serum drug levels and ADAbs can lead 
to nonoptimal clinical treatment decisions. These appar-
ently result in use of TNF-α blockers or non-TNF drugs (or 
escalated dose) without satisfactory response and lead to 
unnecessary costs. To estimate the costs and savings related 
to routine monitoring of drug DLs and ADAbs, we built up 
a hypothetical cohort (N=100) of patients from whom both 
serum DLs and ADAbs were measured. The cost of testing 
was estimated to amount maximally to €20,000 (€200×100 
patients). The costs incurring from nonoptimal treatment 
decision upon secondary loss of response (€1,471/month) 
accumulate with the pace of clinical follow-up visits, and 
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therefore we varied visit frequencies (3, 4.5, and 6 months) 
in the analyses.
Figure 3 illustrates the inverted correlations between the 
incurred costs/savings of systematic testing and the number of 
nonoptimal treatment decisions in the cohort of 100 patients. 
Break-even points lie between two and five out of 100 decisions. 
The ineffective treatment of five patients, only for 3 months or 
2.5 patients for 6 months is estimated to cost approximately 
€22,065 (€1,471×3 months ×5 patients). Consequently, the rou-
tine measurement of both DLs and ADAbs can be cost-saving 
compared to the nontesting scenario, when only 2.5–5 of 100 
patients were treated nonoptimally for 3–6 months.
DL optimal 50.4
Infliximab thresholds:
ADAb U/mL>12 and
DL 2–10 ug/mL
A
ADAb+0.1
ADAb+13.4
ADAb+0.0
ADAb−50.3
ADAb−19.0
ADAb−17.2
DL low 324
DL high 17.2
DL nonoptimal
49.6
DL optimal 42.0
Adalimumab thresholds:
ADAb U/mL>12 and
DL 5–10 ug/mL
ADAb+1.2
ADAb+18.7
ADAb+0.2
ADAb–40.7
ADAb–17.1
ADAb–22.0
DL low 35.8
DL high 22.2
DL nonoptimal 58.0
B
Figure 1 Stratification of a hypothetical patient cohort on the basis of the real-life monitoring result database of this study.
Notes: (A) Expected stratification of 100 patients on adalimumab treatment. (B) Expected stratification of 100 patients on infliximab treatment.
Abbreviations: Dl, drug trough level; aDab+, positive anti-drug antibody analysis result; aDab–, negative anti-drug antibody analysis result.
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Discussion
Adoption of biological drugs has not only improved treat-
ment results in many chronic inflammatory diseases but 
has also led to greatly increased drug costs. Because of the 
budget impact of using biologicals, cost-effectiveness should 
be a major aim. Treatment response needs to be monitored 
clinically and medication discontinued or switched, or in 
rare cases, the dose escalated, in case of insufficient efficacy. 
Considering the anti-TNF monoclonal antibody drugs, their 
immunogenicity potentially leading to generation of ADAbs 
may result in loss of treatment response.
Our study indicates that the probability of nonoptimal 
drug treatment decision is noteworthy among the Finnish 
patients using infliximab and adalimumab if the data on 
individual DLs and ADAbs are not available. Even at very 
low probability of nonoptimal decision, the systematic 
measurement of DLs and ADAbs seems to be cost-saving. 
The main reason for this is that the testing cost of €200 
(combined DL and ADAb) is small compared to the daily 
treatment costs with TNF or non-TNF biologicals.
Based on the data presented in the analysis, a stepwise 
approach could also be suggested: DL is tested for all 
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Figure 2 Markov model of the proportion of patients on adalimumab (A) or infliximab (B) within the modeled 3-year follow-up.
Abbreviation: TnF, tumor necrosis factor.
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Figure 3 costs or savings of systematic testing of drug trough level and aDab.
Notes: The X-axis denotes the percentage of patient cases in which a nonoptimal decision is made in the absence of individual Dl and aDab data. The Y-axis shows the net 
economic effect of routine testing and avoidance of nonoptimal treatment decisions. The three colored lines indicate the net costs or savings depending on the frequency of 
clinical follow-up visits (3-, 4.5-, or 6-month intervals) of the patients on TnF-α blockers.
Abbreviations: Dl, drug trough level; aDab, anti-drug antibody; TnF, tumor necrosis factor.
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patients, but ADAbs are tested for only when DL is low. This 
saves testing costs but carries a risk for nonoptimal decision. 
This holds true especially for adalimumab: a small fraction 
(1.2%) of patients had ADAbs even when DL was optimal. 
The ADAb levels, however, were low (12–30 AU/mL).
Our results are conservative as dose escalation was not 
allowed in the model. One important question is how to value 
utilization of nonoptimal drug. We took only short-term 
health care costs into account, but nonoptimal treatment may 
have long-term and wider societal consequences, too. These 
include, for instance, costs attributed to families, employers, 
and tax payers as well as an impact on health benefits.
The real-life laboratory data on simultaneous DLs and 
ADAbs from a relatively large number of patients enabled the 
analyses. Our dataset is larger than the corresponding datasets 
from other countries and is the first one with real-life data. 
The main limitation of our analysis is that the laboratory data 
also contained sera from patients with indications for TNF 
inhibitors other than RA and that the reasons for testing are 
likely to be various. Our DL and ADAb data were, however, 
relatively similar to most of the previously published data 
from controlled trials with RA patients, thus indicating that 
the aforementioned limitations are unlikely to have a major 
impact on the results regarding the probability of nonoptimal 
drug treatment decision.
Some variability of ADAb positivity can be seen in the 
literature, and this is likely to be caused by variable cutoff of 
ADAb positivity.1 While infliximab ADAbs are found only in 
those patients with low drug level, indicating clinical signifi-
cance, some patients with low level of adalimumab ADAbs 
have also relatively high drug level. Because of this, currently 
in Finland, interpretation of clinically significant adalimumab 
ADAb positivity starts from 30 U/mL, not 12 U/mL. Unneces-
sarily high drug concentrations might allow lower drug dose 
or longer interval.21 It should also be mentioned that various 
ADAb tests are available and that only one was used in this 
study. In order to avoid hardly justifiable change of treatment 
in the patients with DL within the target range and low positive 
adalimumab ADAb level, it has been suggested that the inter-
pretation of DL result should be primary, and ADAb results are 
considered clinically relevant only in case DL is suboptimal.
There are a few potential reasons for low level of drug 
in the absence of ADAbs. First, it is known that there is 
considerable individual variation in metabolizing biological 
drugs. Second, poor compliance can have a dramatic effect 
on drug levels in the case of adalimumab. Third, since the 
ADAb tests measure antibodies against only the Fab2 frag-
ment of the drug, it remains possible (although not shown) 
that some patients with antibodies against Fc part of the 
drug would have low drug levels despite the negative ADAb 
test result.
On the basis of the economic analysis, routine monitor-
ing of TNF-inhibitor DL and ADAb should be included in 
clinical practice. The traditional decision-making based on 
physicians’ experience, tolerance of methotrexate, patients’ 
preferences, etc, can be improved by these tests. This could 
result not only in clinical benefit for the patient by finding 
more quickly the optimal drug for each patient in the case 
of loss of efficacy to one, but also in more cost-effective use 
of biologicals per se. In future, the results of this study need 
to be verified by a prospective study in which the incurred 
costs of monitoring, drugs, and clinical visits are followed 
in a large cohort of patients with RA.
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